Study of ACE-536 in Healthy Postmenopausal Women

Phase 1 Completed 40 enrolled Acceleron Pharma, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to find out whether ACE-536 can be safely given to patients. This study will also look to see if ACE-536 increases red blood cells, the cells that carry oxygen in the body.

Timeline

Start: 2011-09
Primary completion: 2012-09
Completion: 2012-10

Publications

Attie KM, Allison MJ, McClure T, Boyd IE, Wilson DM, Pearsall AE, Sherman ML. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014 Jul;89(7):766-70. doi: 10.1002/ajh.23732. Epub 2014 Apr 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Luspatercept	Protein / enzyme biologic	0.0625 mg/kg	Subcutaneous
Subject	Luspatercept	Protein / enzyme biologic	0.25 mg/kg	Subcutaneous

Study of ACE-536 in Healthy Postmenopausal Women

Summary

Timeline

Publications

Drugs

Indications